{"id":"W2922329974","doi":"10.1200/jco.2019.37.7_suppl.tps342","title":"TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Taxane; Prostate cancer; Internal medicine; Clinical endpoint; Urology; Oncology; Enzalutamide; Progression-free survival; Cancer; Chemotherapy; Clinical trial; Breast cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001635951,0.001913739,0.001520404,0.0007504369,0.0005341005,0.001292421,0.001357164,0.001676335,0.008606697],"category_scores_gemma":[0.0009755595,0.000642585,0.001162377,0.0003793746,0.001107717,0.001313632,0.0005012653,0.003280576,0.001865225],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001040806,"about_ca_system_score_gemma":0.001735457,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001041747,"about_ca_topic_score_gemma":0.003605437,"domain_scores_codex":[0.9996374,0.0001433082,0.00001557151,0.00006821518,0.00004217443,0.00009328009],"domain_scores_gemma":[0.9992967,0.00009314023,0.0001134128,0.0000324824,0.00004392669,0.0004203205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7010245,0.1335489,0.004390444,0.001722961,0.001475738,0.0004307272,0.0005456184,0.003989436,0.04327931,0.000894789,0.009823755,0.09887382],"study_design_scores_gemma":[0.7005669,0.2878373,0.004260866,0.00004369297,0.0003259926,0.0002490114,0.00008601815,0.001363001,0.002264073,0.0004186135,0.002549388,0.0000351926],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797851,0.001891865,0.001105337,0.0009399672,0.0001823044,0.007909247,0.002960855,0.0003812319,0.004844075],"genre_scores_gemma":[0.9804031,0.001407435,0.001834771,0.001541125,0.0001880614,0.005142583,0.003156063,0.00006644324,0.006260376],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008606697,"threshold_uncertainty_score":0.02879226,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2016399061329101,"score_gpt":0.4849983996560712,"score_spread":0.283358493523161,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}